Evaluating the Potential of Microdosing 1cp-LSD for the Treatment of Canine Anxiety: A One-Month Case Study

Elisa Hernández-Álvarez, Lucas F. Borkel, Jaime Rojas-Hernández, Domingo J. Quintana-Hernández, Ignacio García-Serrano, Tobías Fernández-Borkel, Manuel Zumbado, Luis Alberto Henríquez-Hernández

DOI: https://doi.org/10.1002/vms3.70486

​

This pilot study explored the potential of microdosing 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) to treat canine anxiety. A single-case study was conducted on a 13-year-old female dog with severe separation anxiety, who was treated with 5 µg of 1cp-LSD every 3 days for a month. Anxiety was assessed before, after, and 1 month following treatment using a validated questionnaire. The owner's attachment style was assessed using a validated scale. The dog's anxiety score significantly decreased from 29 (severe) to 14 (moderate) after treatment. A reduction in anxiety levels was observed, characterized by decreased destructive behaviour and shorter durations of vocalization. This improvement was sustained 1 month following treatment, although vocalization frequency increased. These findings suggest potential therapeutic efficacy of microdosing 1cp-LSD in managing canine anxiety; however, the absence of a control group makes it difficult to determine whether the observed effects are due to 1cp-LSD, owner bias, or natural variability in the dog's behaviour. Additional studies with blinded protocols and larger sample sizes are necessary to validate these findings and further explore the impact of owner attachment on canine anxiety.

​

​

Therapeutic benefit versus epistemic risk: Need for empirical research in psychedelic epistemology

Lucas F. Borkel, Jaime Rojas-Hernández, Domingo J. Quintana-Hernández, Luis Alberto Henríquez-Hernández

DOI: https://doi.org/10.1016/j.jpsychires.2025.05.039